Abiopharma

🔍 Joshi Aman (Executive)

Company: Bloom Energy Corp (BE)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Sold 19,944 shares of Class A Common Stock at $154.85 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: false | shares_owned_after: 190,521.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 168,750 shares of Stock Option (Right to Buy) at $9.08 per share (Derivative)
  Date: 2026-03-15 | Code: A | Expires: 2034-03-01 | Exercise: 2026-03-15 | equity_swap_involved: false | shares_owned_after: 302,022.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 90,000 shares of Stock Option (Right to Buy) at $11.9 per share (Derivative)
  Date: 2026-03-15 | Code: A | Expires: 2034-08-29 | Exercise: 2026-03-15 | equity_swap_involved: false | shares_owned_after: 180,000.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2025.
• F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $150.58 to $161.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
• F3: On March 1, 2024, the Reporting Person was granted an option to purchase 450,000 shares of the Company's Class A Common Stock. The option vests in four annual installments based on the Reporting Person's satisfaction of certain performance criteria, and subject to the Reporting Person's continued service through each applicable vesting date. The performance criteria for the second installment exceeded target as determined by the Compensation Committee on February 19, 2026, which resulted in a payout of 150% of target, resulting in the vesting of the option to purchase 168,750 shares of the Company's Class A Common Stock.
• F4: On August 29, 2024, the Reporting Person was granted an option to purchase 180,000 shares of the Company's Class A Common Stock. The option vests in three annual installments based on the Reporting Person's satisfaction of certain performance criteria, and subject to the Reporting Person's continued service through each applicable vesting date. The performance criteria for the second installment exceeded target as determined by the Compensation Committee on February 19, 2026, which resulted in a payout of 150% of target, resulting in the vesting of the option to purchase 90,000 shares of the Company's Class A Common Stock.